Axsome Therapeutics (STU:19X) LT-Debt-to-Total-Asset : 0.33 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Axsome Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.33.

Axsome Therapeutics's long-term debt to total assets ratio increased from Dec. 2023 (0.32) to Dec. 2024 (0.33). It may suggest that Axsome Therapeutics is progressively becoming more dependent on debt to grow their business.

Axsome Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Axsome Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics LT-Debt-to-Total-Asset Chart

Axsome Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.26

0.56

0.28

0.32

0.33

Axsome Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.32	0.34	0.35	0.34	0.33

Axsome Therapeutics LT-Debt-to-Total-Asset Calculation

Axsome Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	181.163	/	542.916
	=	0.33

Axsome Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	181.163	/	542.916
	=	0.33

Axsome Therapeutics (STU:19X) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Axsome Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AXSM:USA 0HKF:UK 19X:Germany

Address

One World Trade Center, 22nd Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines